CD123-CPI ADC (Pfizer)

N/A

Report date: 2025/03/19 09:02:55

Base Information

Drug NameCD123-CPI ADC (Pfizer)
Drug Alias NameCD123 cyclopropylpyrroloindole antibody-drug conjugate (Pfizer Oncology)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionInterleukin-3 receptor subunit alpha inhibitorsDNA modulators
TargetsInterleukin-3 receptor subunit alphaDNA
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesPfizer Inc
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A